The oral solid dose (OSD) market is $541 billon1 and has shown steady growth over the past few years. 72% of new approved drugs in 2021 were small molecules, and nearly 50% of new drugs approved in 2021 were OSD.2 Emerging companies hold >70% of the total OSD clinical development pipeline and more than 80% of the OSD preclinical development pipeline.3 It is causing a shift in how companies plan and execute the development and manufacturing of OSD drug products. Thermo Fisher Scientific provides a range of early development OSD solutions that can address your small molecule’s unique needs and challenges, while being backed by technical experts and a global network. Leverage our early development services to help:
1 IQVIA MIDAS Global Data (February 2022), Thermo Fisher Scientific internal analysis.
2 www.fda.gov. 3 Thermo Fisher Scientific internal analysis, data from December 2021.
Learn about our Oral Solid Dose Dosage Forms.